Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Most Undervalued Oncolytics Company On The Nasdaq

<< Previous

Bullboard Posts

Next >>

Post by laroplexon Oct 05, 2023 12:21pm

228 Views

Post# 35671267

The Most Undervalued Oncolytics Company On The Nasdaq

https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/?utm_source=taboola&utm_medium=referral&tblci=GiAx6KiRfXbfmlTXyceEQ1C1R83j5zOvdtYVtlSpHKK3cSCelmIooIuytrfA247mAQ#tblciGiAx6KiRfXbfmlTXyceEQ1C1R83j5zOvdtYVtlSpHKK3cSCelmIooIuytrfA247mAQ

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario